Revolution Medicines Inc. (RVMD): Price and Financial Metrics
RVMD Price/Volume Stats
Current price | $30.94 | 52-week high | $35.60 |
Prev. close | $31.83 | 52-week low | $15.44 |
Day low | $30.86 | Volume | 2,380,200 |
Day high | $32.17 | Avg. volume | 1,392,636 |
50-day MA | $29.48 | Dividend yield | N/A |
200-day MA | $27.40 | Market Cap | 5.10B |
RVMD Stock Price Chart Interactive Chart >
RVMD POWR Grades
- RVMD scores best on the Value dimension, with a Value rank ahead of 47% of US stocks.
- The strongest trend for RVMD is in Stability, which has been heading down over the past 26 weeks.
- RVMD ranks lowest in Growth; there it ranks in the 2nd percentile.
RVMD Stock Summary
- REVOLUTION MEDICINES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 10.8% of US listed stocks.
- Of note is the ratio of REVOLUTION MEDICINES INC's sales and general administrative expense to its total operating expenses; only 4.69% of US stocks have a lower such ratio.
- With a price/sales ratio of 117.19, REVOLUTION MEDICINES INC has a higher such ratio than 97.93% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to REVOLUTION MEDICINES INC are XBIT, CKPT, NRIX, ARVN, and IDYA.
- RVMD's SEC filings can be seen here. And to visit REVOLUTION MEDICINES INC's official web site, go to www.revmed.com.
RVMD Valuation Summary
- In comparison to the median Healthcare stock, RVMD's price/sales ratio is 5359.09% higher, now standing at 120.1.
- Over the past 47 months, RVMD's EV/EBIT ratio has gone up 27.7.
Below are key valuation metrics over time for RVMD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
RVMD | 2023-12-29 | 120.1 | 3.8 | -9.5 | -8.5 |
RVMD | 2023-12-28 | 123.0 | 3.8 | -9.7 | -8.7 |
RVMD | 2023-12-27 | 122.7 | 3.8 | -9.7 | -8.7 |
RVMD | 2023-12-26 | 121.0 | 3.8 | -9.6 | -8.6 |
RVMD | 2023-12-22 | 114.3 | 3.6 | -9.0 | -8.0 |
RVMD | 2023-12-21 | 110.0 | 3.4 | -8.7 | -7.7 |
RVMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RVMD has a Quality Grade of D, ranking ahead of 13.97% of graded US stocks.
- RVMD's asset turnover comes in at 0.059 -- ranking 312th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows RVMD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.059 | 1 | -0.340 |
2021-03-31 | 0.068 | 1 | -0.328 |
2020-12-31 | 0.083 | 1 | -0.328 |
2020-09-30 | 0.107 | 1 | -0.361 |
2019-12-31 | 0.256 | 1 | -1.357 |
RVMD Price Target
For more insight on analysts targets of RVMD, see our RVMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $33.00 | Average Broker Recommendation | 1.57 (Moderate Buy) |
Revolution Medicines Inc. (RVMD) Company Bio
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Latest RVMD News From Around the Web
Below are the latest news stories about REVOLUTION MEDICINES INC that investors may wish to consider to help them evaluate RVMD as an investment opportunity.
Revolution Medicines Inc Insider Sells SharesMargaret Horn, COO of Revolution Medicines Inc (NASDAQ:RVMD), sold 7,993 shares of the company on December 18, 2023, according to a recent SEC Filing. |
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug DevelopmentThese pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. |
Insider Sell Alert: COO Margaret Horn Sells 5,000 Shares of Revolution Medicines Inc (RVMD)In the realm of biopharmaceuticals, insider transactions are often scrutinized for insights into the company's health and future prospects. |
A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who own 74% must be happyKey Insights Given the large stake in the stock by institutions, Revolution Medicines' stock price might be vulnerable... |
3 Biotech Stocks That Could Boom or Bust by 2025Biotech stocks are popular with investors because they sometimes provide tremendous rewards. |
RVMD Price Returns
1-mo | 4.85% |
3-mo | 20.44% |
6-mo | 1.51% |
1-year | 42.12% |
3-year | -36.05% |
5-year | N/A |
YTD | 7.88% |
2023 | 20.40% |
2022 | -5.36% |
2021 | -36.42% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...